25.02.2020 23:02:00
|
Kinaxis Inc. Reports Fourth Quarter 2019 Results
- Q4 SaaS revenue grows 26% to $32.0 million; full year SaaS revenue grows 22%
- Q4 2019 total revenue grows 47% to $56.3 million; full year total revenue grows 27%
- Q4 adjusted EBITDA(1) margin of 32%; full year adjusted EBITDA(1) margin of 30%
OTTAWA, Feb. 25, 2020 /CNW/ - Kinaxis® (TSX: KXS) , the leader in empowering people to make confident supply chain decisions, today reported results for its fourth quarter ended December 31, 2019. All amounts are in U.S. dollars. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated.
"I am extremely pleased with our Q4 and overall 2019 performance, and happy to report that we were able to meet or exceed our 2019 annual guidance for all key financial metrics," said John Sicard, President and Chief Executive Officer of Kinaxis. "Bookings were very strong in the fourth quarter driving our multi-year SaaS revenue backlog up by 40% from a year ago. Our success is a result of closing new customers in the quarter, including recently announced Dr. Reddy's Laboratories and Lundbeck, as well as signing existing customer renewals, including Schneider Electric, Unilever and Merck. Our partners continue to be key influencers in the healthy and continuously growing market, and they continue to share in our success as a result. It is with confidence in our market position that we will continue to make strategic investments across our operations in 2020 to spur future growth."
Q4 2019 Highlights | |||
$ USD thousands, except as otherwise indicated | Q4 2019 | Q4 2018 | Change |
Total Revenue | 56,312 | 38,299 | 47% |
SaaS | 32,006 | 25,492 | 26% |
Subscription term license | 12,120 | 2,390 | 407% |
Gross profit | 41,440 | 25,909 | 60% |
(74%) | (68%) | ||
Profit | 7,831 | 2,925 | 168% |
($0.29/diluted share) | ($0.11/diluted share) | ||
Adjusted EBITDA(1) | 18,134 | 8,986 | 102% |
(32%) | (23%) | ||
Cash from operating activities | 8,025 | 6,654 | 21% |
FY 2019 Highlights | |||
$ USD thousands, except as otherwise indicated | FY 2019 | FY 2018 | Change |
Total Revenue | 191,549 | 150,727 | 27% |
SaaS | 118,860 | 97,157 | 22% |
Subscription term license | 26,218 | 9,935 | 164% |
Gross profit | 137,699 | 103,695 | 33% |
(72%) | (69%) | ||
Profit | 23,331 | 14,408 | 62% |
($0.87/diluted share) | ($0.54/diluted share) | ||
Adjusted EBITDA(1) | 57,727 | 41,687 | 38% |
(30%) | (28%) | ||
Cash from operating activities | 36,599 | 27,915 | 31% |
1 "Adjusted EBITDA" is a non-IFRS measure and is not a recognized, defined or a standardized measure under IFRS. This measure as well as other non-IFRS financial measures reported by Kinaxis are defined in the "Non-IFRS Measures" section of this news release. |
Financial Guidance and Outlook | |
Kinaxis is initiating 2020 fiscal year financial targets, as follows: | |
FY 2020 Guidance | |
Total revenue | $211-215 million |
SaaS | 23-25% growth |
Subscription term license | $12-14 million |
Adjusted EBITDA margin | 20-23% of revenue |
This guidance is provided to enhance visibility into Kinaxis' expectations for financial targets for the periods indicated. Please refer to the section regarding forward-looking statements that forms an integral part of this release.
The nature of the company's long-term contracts provides visibility into future, contracted revenue. The following table presents revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at December 31, 2019.
$USD millions | 2020 | 2021 | 2022 and later | Q4 2019 Total | Q4 2018 Total | Change |
SaaS | 122.1 | 91.8 | 96.7 | 310.6 | 222.3 | 40% |
Maintenance and support | 11.1 | 8.3 | 4.9 | 24.3 | 15.0 | 62% |
Subscription term license | 4.5 | - | - | 4.5 | 0.2 | - |
Total | 137.8 | 100.1 | 101.6 | 339.4 | 237.5 | 43% |
This press release, along with the financial statements and MD&A for the three and twelve months ended December 31, 2019, are available on Kinaxis' website and on SEDAR at www.sedar.com.
Conference Call
Kinaxis will host a conference call tomorrow, February 26, 2020, to discuss these results. John Sicard, Chief Executive Officer, and Richard Monkman, Chief Financial Officer, will host the call starting at 8:30 a.m. Eastern Time. A question and answer session will follow management's presentation.
Date: | Wednesday, February 26, 2020 |
Time: | 8:30 a.m. Eastern Time |
Webcast: | https://bit.ly/2u5uBpa |
Dial-in number: | (647) 427-7450 or (888) 231-8191 |
Replay: | (416) 849-0833 or (855) 859-2056 |
Available until 11:59 p.m. EDT, Wednesday, March 4, 2020 | |
Reference number: | 4386215 |
Please call the conference telephone number five to ten minutes prior to the start time. An operator will register your name and organization.
About Kinaxis Inc.
Eliminating volatility in your supply chain is impossible, but managing it is not. Trusted by top brands, Kinaxis® gives people the confidence to know they are making the best supply chain planning decisions to maximize business performance. We solve complex business problems in easy-to-understand ways by combining human and machine intelligence to plan for any future, monitor risks and opportunities and respond at the pace of change. With the support of our community of supply chain experts and using our unique concurrent planning technique and single integrated planning platform, customers can realize higher revenue, lower costs and fewer risks. For more Kinaxis news, follow us on LinkedIn, Twitter or Facebook.
Non-IFRS Measures
This news release contains non-IFRS measures, specifically, Adjusted profit, Adjusted diluted earnings per share, Adjusted EBITDA and Adjusted EBITDA margin. We use Adjusted profit and Adjusted diluted earnings per share, which remove the impact of our share-based compensation plans, to measure our performance as these measurements better align the reporting of our results and improve comparability against our peers. We use Adjusted EBITDA to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess our ability to meet our capital expenditure and working capital requirements. Adjusted profit, Adjusted diluted earnings per share and Adjusted EBITDA are not recognized, defined or standardized measures under IFRS. Our definition of Adjusted profit, Adjusted diluted earnings per share and Adjusted EBITDA will likely differ from that used by other companies (including our peers) and therefore comparability may be limited. Non-IFRS measures should not be considered a substitute for or in isolation from measures prepared in accordance with IFRS. Investors are encouraged to review our financial statements and disclosures in their entirety and are cautioned not to put undue reliance on non-IFRS measures and view them in conjunction with the most comparable IFRS financial measures. Kinaxis has reconciled Adjusted profit and Adjusted EBITDA to the most comparable IFRS financial measure as follows:
Three months ended | Year ended | ||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||
(In thousands of USD) | |||||||||||
Profit | $ | 7,831 | $ | 2,925 | $ | 23,331 | $ | 14,408 | |||
Share-based compensation | 3,177 | 2,924 | 13,367 | 11,568 | |||||||
Adjusted profit | $ | 11,008 | $ | 5,849 | $ | 36,698 | $ | 25,976 | |||
Income tax expense | 4,484 | 1,796 | 11,932 | 8,068 | |||||||
Depreciation | 3,212 | 2,571 | 11,908 | 9,272 | |||||||
Foreign exchange loss | 40 | (22) | 226 | 181 | |||||||
Net finance income | (610) | (1,208) | (3,037) | (1,810) | |||||||
7,126 | 3,137 | 21,029 | 15,711 | ||||||||
Adjusted EBITDA | $ | 18,134 | $ | 8,986 | $ | 57,727 | $ | 41,687 | |||
Adjusted EBITDA as a percentage of revenue | 32% | 23% | 30% | 28% |
Note: | |
(1) | We adopted IFRS 15 and 16 effective January 1, 2018. Under this adoption, the comparative information for 2017 was not restated. |
Forward-Looking Statements
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to our expectations for:
- growth of annual total revenue, annual SaaS and Subscription term licenses revenue, and our expectations for Adjusted EBITDA margin achievement, in each case looking forward for our fiscal year ending December 31, 2020; and
- contracted revenue in future periods, including 2020, 2021 and 2022.
This release also includes forward-looking statements as to Kinaxis' growth opportunities and the potential benefits of, and markets and demand for, Kinaxis' products and services. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of Kinaxis' products and services compared to competitive offerings in the industry.
In particular, our guidance for 2020 annual total revenue, annual SaaS and Subscription term license revenue and annual Adjusted EBITDA margin, is subject to certain assumptions and associated risks including:
- our ability to win business from new customers and expand business from existing customers;
- the timing of new customer wins and expansion decisions by our existing customers;
- maintaining our current customer retention levels; and
- with respect to Adjusted EBITDA, our ability to contain expense levels while expanding our business.
Our guidance and commentary for achievement of contracted revenue in future periods, including in 2020, 2021 and 2022, is based on assumptions and associated risks including:
- our ability to satisfy material unperformed obligations under our long-term contracts; and
- the continued financial capacity and creditworthiness of our customers under long-term contracts.
These and other assumptions, risks and uncertainties may cause Kinaxis' actual results, performance, achievements and developments to differ materially from the results, performance, achievements or developments expressed or implied by forward-looking statements. Material risks and uncertainties relating to our business are described under the headings "Forward-Looking Statements" and "Risks and Uncertainties" in our annual MD&A dated February 25, 2020, under the heading "Risk Factors" in our Annual Information Form dated February 28, 2019 and in our other public documents filed with Canadian securities regulatory authorities, which are available at www.sedar.com. Forward-looking statements are provided to help readers understand management's expectations as at the date of this release and may not be suitable for other purposes. Readers are cautioned not to place undue reliance on forward-looking statements. Kinaxis assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.
Kinaxis Inc. | ||
Condensed Consolidated Statements of Financial Position | ||
As at December 31, 2019 and December 31, 2018 | ||
(Expressed in thousands of USD) | ||
2019 | 2018 | |
Assets | ||
Current assets: | ||
Cash and cash equivalents | 182,284 | 126,144 |
Short-term investments | 30,319 | 55,404 |
Trade and other receivables | 81,336 | 64,330 |
Prepaid expenses | 6,534 | 5,815 |
300,473 | 251,693 | |
Non-current assets: | ||
Property and equipment | 25,704 | 22,785 |
Right-of-use assets | 8,671 | 8,873 |
Contract acquisition costs | 15,497 | 13,902 |
Unbilled receivables | 249 | 457 |
Deferred tax assets | 149 | 49 |
350,743 | 297,759 | |
Liabilities and Shareholders' Equity | ||
Current liabilities: | ||
Trade payables and accrued liabilities | 20,770 | 21,623 |
Deferred revenue | 83,673 | 78,496 |
Lease obligations | 2,288 | 2,572 |
106,731 | 102,691 | |
Non-current liabilities: | ||
Lease obligations | 6,818 | 6,311 |
Deferred tax liabilities | 7,092 | 4,075 |
13,910 | 10,386 | |
Shareholders' equity: | ||
Share capital | 140,961 | 124,951 |
Contributed surplus | 30,392 | 24,284 |
Accumulated other comprehensive loss | (348) | (319) |
Retained earnings | 59,097 | 35,766 |
230,102 | 184,682 | |
350,743 | 297,759 |
Kinaxis Inc. | ||||||
Condensed Consolidated Statements of Comprehensive Income | ||||||
For the three months and years ended December 31, 2019 and 2018 | ||||||
(Expressed in thousands of USD, except share and per share data) | ||||||
For the three months ended | For the year ended | |||||
2019 | 2018 | 2019 | 2018 | |||
Revenue | 56,312 | 38,299 | 191,549 | 150,727 | ||
Cost of revenue | 14,872 | 12,390 | 53,850 | 47,032 | ||
Gross profit | 41,440 | 25,909 | 137,699 | 103,695 | ||
Operating expenses: | ||||||
Selling and marketing | 13,747 | 10,285 | 44,270 | 35,055 | ||
Research and development | 9,443 | 7,105 | 34,125 | 27,626 | ||
General and administrative | 6,505 | 5,028 | 26,852 | 20,167 | ||
29,695 | 22,418 | 105,247 | 82,848 | |||
11,745 | 3,491 | 32,452 | 20,847 | |||
Other income (expense): | ||||||
Foreign exchange gain (loss) | (40) | 22 | (226) | (181) | ||
Net finance income | 610 | 1,208 | 3,037 | 1,810 | ||
570 | 1,230 | 2,811 | 1,629 | |||
Profit before income taxes | 12,315 | 4,721 | 35,263 | 22,476 | ||
Income tax expense | 4,484 | 1,796 | 11,932 | 8,068 | ||
Profit | 7,831 | 2,925 | 23,331 | 14,408 | ||
Other comprehensive income (loss): | ||||||
Items that are or may be reclassified subsequently to profit or loss: | ||||||
Foreign currency translation differences - foreign operations | 100 | 178 | (29) | (35) | ||
Total comprehensive income | 7,931 | 3,103 | 23,302 | 14,373 | ||
Basic earnings per share | 0.30 | 0.11 | 0.89 | 0.56 | ||
Weighted average number of basic Common Shares | 26,294,645 | 26,037,096 | 26,180,034 | 25,820,518 | ||
Diluted earnings per share | 0.29 | 0.11 | 0.87 | 0.54 | ||
Weighted average number of diluted Common Shares | 27,184,684 | 26,812,260 | 26,967,805 | 26,824,435 |
Kinaxis Inc. | |||||
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity | |||||
For the years ended December 31, 2019 and 2018 | |||||
(Expressed in thousands of USD) | |||||
Accumulated | |||||
other | Retained | ||||
Share | Contributed | comprehensive | earnings | ||
capital | surplus | loss | (deficit) | Total equity | |
Balance, December 31, 2017 | 108,253 | 19,294 | (284) | (2,475) | 124,788 |
Adjustment on initial application of IFRS 15 | - | - | - | 23,833 | 23,833 |
Balance, January 1, 2018 | 108,253 | 19,294 | (284) | 21,358 | 148,621 |
Profit | - | - | - | 14,408 | 14,408 |
Other comprehensive loss | - | - | (35) | - | (35) |
Total comprehensive income (loss) | - | - | (35) | 14,408 | 14,373 |
Share options exercised | 14,012 | (3,892) | - | - | 10,120 |
Restricted share units vested | 1,834 | (1,834) | - | - | - |
Deferred share units exercised | 852 | (852) | - | - | - |
Share based payments | - | 11,568 | - | - | 11,568 |
Total shareholder transactions | 16,698 | 4,990 | - | - | 21,688 |
Balance, December 31, 2018 | 124,951 | 24,284 | (319) | 35,766 | 184,682 |
Profit | - | - | - | 23,331 | 23,331 |
Other comprehensive loss | - | - | (29) | - | (29) |
Total comprehensive income (loss) | - | - | (29) | 23,331 | 23,302 |
Share options exercised | 12,042 | (3,291) | - | - | 8,751 |
Restricted share units vested | 3,968 | (3,968) | - | - | - |
Share based payments | - | 13,367 | - | - | 13,367 |
Total shareholder transactions | 16,010 | 6,108 | - | - | 22,118 |
Balance, December 31, 2019 | 140,961 | 30,392 | (348) | 59,097 | 230,102 |
Kinaxis Inc. | |||||||
Condensed Consolidated Statements of Cash Flows | |||||||
For the three months and years ended December 31, 2019 and 2018 | |||||||
(Expressed in thousands of USD) | |||||||
For the three months ended December 31, | For the year ended December 31, | ||||||
2019 | 2018 | 2019 | 2018 | ||||
Cash flows from operating activities: | |||||||
Profit | 7,831 | 2,925 | 23,331 | 14,408 | |||
Items not affecting cash: | |||||||
Depreciation of property and equipment and right-of-use assets | 3,212 | 2,571 | 11,908 | 9,272 | |||
Share-based payments | 3,177 | 2,924 | 13,367 | 11,568 | |||
Investment tax credits recoverable | - | - | - | 911 | |||
Net finance income | (610) | (1,208) | (3,037) | (1,810) | |||
Income tax expense | 4,484 | 1,796 | 11,932 | 8,068 | |||
Change in operating assets and liabilities | (8,074) | (4,089) | (9,161) | (13,215) | |||
Interest received | 660 | 1,100 | 3,653 | 2,413 | |||
Interest paid | (112) | (62) | (531) | (773) | |||
Income taxes paid | (2,543) | 697 | (14,863) | (2,927) | |||
8,025 | 6,654 | 36,599 | 27,915 | ||||
Purchase of property and equipment | (1,378) | (1,198) | (11,719) | (12,310) | |||
Purchase of short-term investments | (10,000) | (27,597) | (60,108) | (112,684) | |||
Redemption of short-term investments | 10,000 | 42,539 | 85,108 | 112,588 | |||
(1,378) | 13,744 | 13,281 | (12,406) | ||||
Payment of lease obligations | (679) | (582) | (2,674) | (2,160) | |||
Common shares issued on exercise of stock options | 4,428 | 478 | 8,751 | 10,120 | |||
3,749 | (104) | 6,077 | 7,960 | ||||
Increase in cash and cash equivalents | 10,396 | 20,294 | 55,957 | 23,469 | |||
Cash and cash equivalents, beginning of period | 171,957 | 106,040 | 126,144 | 103,392 | |||
Effects of exchange rates on cash and cash equivalents | (69) | (190) | 183 | (717) | |||
Cash and cash equivalents, end of period | 182,284 | 126,144 | 182,284 | 126,144 | |||
SOURCE Kinaxis Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!